Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
1.190
-0.050 (-4.03%)
At close: Mar 11, 2026, 4:00 PM EDT
1.182
-0.008 (-0.71%)
After-hours: Mar 11, 2026, 7:59 PM EDT
Humacyte Revenue
Humacyte had revenue of $753.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $1.57M.
Revenue (ttm)
$1.57M
Revenue Growth
n/a
P/S Ratio
145.58
Revenue / Employee
$7,141
Employees
220
Market Cap
229.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.57M | 302.00K | 23.91% |
| Dec 31, 2021 | 1.26M | -228.00K | -15.29% |
| Dec 31, 2020 | 1.49M | -4.70M | -75.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Keros Therapeutics | 244.06M |
| Protalix BioTherapeutics | 61.84M |
| Editas Medicine | 40.52M |
| Voyager Therapeutics | 31.32M |
| Sol-Gel Technologies | 18.97M |
| MediWound | 16.96M |
| Cartesian Therapeutics | 2.80M |
HUMA News
- 1 day ago - Humacyte, Inc. (HUMA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 days ago - Humacyte, Inc. (HUMA) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 9 days ago - Humacyte To Participate in Upcoming Investor Conferences - GlobeNewsWire
- 21 days ago - Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting - GlobeNewsWire
- 4 weeks ago - Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels - GlobeNewsWire
- 2 months ago - Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications - GlobeNewsWire
- 2 months ago - Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel - GlobeNewsWire
- 2 months ago - Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair - GlobeNewsWire